‌

US Patent 12122823 Isoform-selective TGFB1 inhibitors and use thereof

Patent 12122823 was granted and assigned to Scholar Rock on October, 2024 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors

Is a

0

Patent attributes

Patent Applicant

0

Current Assignee

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Stefan Wawersik0

Allan Capili0

Christopher Chapron0

Thomas Schurpf0

Susan Lin0

Justin W. Jackson0

Caitlin Stein0

Alan Buckler0

...

Date of Patent

October 22, 2024

0

Patent Application Number

174064000

Date Filed

August 19, 2021

0

Patent Citations

US Patent 9580500 Compositions and methods for growth factor modulation

0

US Patent 9758576 Compositions and methods for growth factor modulation

0

US Patent 9758577 Compositions and methods for growth factor modulation

0

US Patent 9573995 Compositions and methods for growth factor modulation

0

US Patent 10981981 Compositions and methods for growth factor modulation

0

US Patent 9399676 Compositions and methods for growth factor modulation

0

US Patent 10597443 Compositions and methods for growth factor modulation

0

Patent Primary Examiner

0

Patent abstract

Disclosed herein are monoclonal antibodies and antigen-binding fragments thereof capable of selectively inhibiting TGFβ1 with high potency. Related compositions, methods and therapeutic use are also disclosed.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 12122823 Isoform-selective TGFB1 inhibitors and use thereof

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool

By using this site, you agree to our Terms of Service.